Archives of Pharmacal Research

, Volume 36, Issue 6, pp 651–659 | Cite as

Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia

  • Eun Ji Park
  • Sarmila Amatya
  • Myung Sun Kim
  • Jong Hoon Park
  • Eunyoung Seol
  • Heeyong Lee
  • Young-Hee Shin
  • Dong Hee Na
Review

Abstract

Antipsychotic drugs have been used to treat patients with schizophrenia and other psychotic disorders. Long-acting injectable antipsychotic drugs are useful for improving medication compliance with a better therapeutic option to treat patients who lack insight or adhere poorly to oral medication. Several long-acting injectable antipsychotic drugs are clinically available. Haloperidol decanoate and fluphenazine decanoate are first-generation depot drugs, but the use of these medicines has declined since the advent of second-generation depot agents, such as long-acting risperidone, paliperidone palmitate, and olanzapine pamoate. The second-generation depot drugs are better tolerated and have fewer adverse neurological side effects. Long-acting injectable risperidone, the first depot formulation of an atypical antipsychotic drug, was prepared by encapsulating risperidone into biodegradable microspheres. Paliperidone palmitate is an aqueous suspension of nanocrystal molecules, and olanzapine pamoate is a microcrystalline salt of olanzapine and pamoic acid suspended in aqueous solution. This review summarizes the characteristics and recent research of formulations of each long-acting injectable antipsychotic drug.

Keywords

Antipsychotic drugs Long-acting formulation Olanzapine pamoate Paliperidone palmitate Risperidone Schizophrenia 

Notes

Acknowledgments

This research was financially supported by the Ministry of Knowledge Economy (MKE) and Korea Institute for Advancement in Technology (KIAT) through the Research and Development for Regional Industry. This research was also supported by the leading industry and equipments of the ChungCheong Leading Industry Office of the Korean Ministry of Knowledge.

References

  1. Altamura, A.C., F. Sassella, A. Santini, C. Montresor, S. Fumagalli, and E. Mundo. 2003. Intramuscular preparations of antipsychotics: Uses and relevance in clinical practice. Drugs 63: 493–512.PubMedCrossRefGoogle Scholar
  2. Baweja, R., K. Sedky, and S. Lippmann. 2012. Long-acting antipsychotic medications. Current Drug Targets 13: 555–560.PubMedCrossRefGoogle Scholar
  3. Bishara, D. 2010. Once-monthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatric Disease and Treatment 6: 561–572.PubMedCrossRefGoogle Scholar
  4. Cha, Y., and C.G. Pitt. 1988. A one-week subdermal delivery system for l-methadone based on biodegradable microcapsules. Journal of Controlled Release 8: 69–78.CrossRefGoogle Scholar
  5. Choi, J.S., K. Seo, and J.W. Yoo. 2012. Recent advances in PLGA particulate systems for drug delivery. Journal of Pharmaceutical Investigation 42: 155–163.CrossRefGoogle Scholar
  6. Chue, P., and J. Chue. 2012a. A review of paliperidone palmitate. Expert Review of Neurotherapeutics 12: 1383–1397.PubMedCrossRefGoogle Scholar
  7. Chue, P., and J. Chue. 2012b. A review of olanzapine pamoate. Expert Opinion on Pharmacotherapy 13: 1661–1670.PubMedCrossRefGoogle Scholar
  8. Eerdekens, M., I. Van Hove, B. Remmerie, and E. Mannaert. 2004. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophrenia Research 70: 91–100.PubMedCrossRefGoogle Scholar
  9. Ereshefsky, L., and C.A. Mascarenas. 2003. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. Journal of Clinical Psychiatry 64: 18–23.PubMedGoogle Scholar
  10. Ereshefsky, L., and E. Mannaert. 2005. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: Potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs in R&D 6: 129–137.CrossRefGoogle Scholar
  11. Fleischhacker, W.W. 2009. Second-generation antipsychotic long-acting injections: Systematic review. British Journal of Psychiatry 52: S29–S36.CrossRefGoogle Scholar
  12. Froemming, J.S., Y.W. Lam, M.W. Jann, and C.M. Davis. 1989. Pharmacokinetics of haloperidol. Clinical Pharmacokinetics 17: 396–423.PubMedCrossRefGoogle Scholar
  13. Harrison, T.S., and K.L. Goa. 2004. Long-acting risperidone: A review of its use in schizophrenia. CNS Drugs 18: 113–132.PubMedCrossRefGoogle Scholar
  14. Horacek, J., V. Bubenikova-Valesova, M. Kopecek, T. Palenicek, C. Dockery, P. Mohr, and C. Höschl. 2006. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20: 389–409.PubMedCrossRefGoogle Scholar
  15. Hu, Z., Y. Liu, W. Yuan, F. Wu, J. Su, and T. Jin. 2011. Effect of bases with different solubility on the release behavior of risperidone loaded PLGA microspheres. Colloids and Surfaces B: Biointerfaces 86: 206–211.CrossRefGoogle Scholar
  16. Iqbal, M.M., A. Rahman, Z. Husain, S.Z. Mahmud, W.G. Ryan, and J.M. Feldman. 2003. Clozapine: A clinical review of adverse effects and management. Annals of Clinical Psychiatry 15: 33–48.PubMedCrossRefGoogle Scholar
  17. Janssen, P.A., C.J. Niemegeers, F. Awouters, K.H. Schellekens, A.A. Megens, and T.F. Meert. 1988. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. Journal of Pharmacology and Experimental Therapeutics 244: 685–693.PubMedGoogle Scholar
  18. Kane, J.M. 2006. Utilization of long-acting antipsychotic medication in patient care. CNS Spectrums 11: 1–7.PubMedGoogle Scholar
  19. Klose, D., F. Siepmann, K. Elkharraz, and J. Siepmann. 2008. PLGA-based drug delivery systems: Importance of the type of drug and device geometry. International Journal of Pharmaceutics 354: 95–103.PubMedCrossRefGoogle Scholar
  20. Knox, E.D., and G.L. Stimmel. 2004. Clinical review of a long-acting, injectable formulation of risperidone. Clinical Therapeutics 26: 1994–2002.PubMedCrossRefGoogle Scholar
  21. Kramer, M., R. Litman, D. Hough, R. Lane, P. Lim, Y. Liu, and M. Eerdekens. 2010. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. International Journal of Neuropsychopharmacology 13: 635–647.PubMedCrossRefGoogle Scholar
  22. Leucht, S., T.R. Barnes, W. Kissling, R.R. Engel, C. Correll, and J.M. Kane. 2003. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory metaanalysis of randomized, controlled trials. American Journal of Psychiatry 160: 1209–1222.PubMedCrossRefGoogle Scholar
  23. Leucht, S., M. Tardy, K. Komossa, S. Heres, W. Kissling, G. Salanti, and J.M. Davis. 2012. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. Lancet 379: 2063–2071.PubMedCrossRefGoogle Scholar
  24. Leysen, J.E., W. Gommeren, A. Eens, D. de Chaffoy de Courcelles, J.C. Stoof, and P.A. Janssen. 1988. Biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacology and Experimental Therapeutics 247: 661–670.PubMedGoogle Scholar
  25. Lindenmayer, J.P. 2010. Long-acting injectable antipsychotics: Focus on olanzapine pamoate. Journal of Neuropsychiatric Disease and Treatment 6: 261–267.CrossRefGoogle Scholar
  26. Luo, J.P., J.W. Hubbard, and K.K. Midha. 1997. Studies on the mechanism of absorption of depot neuroleptics: Fluphenazine decanoate in sesame oil. Pharmaceutical Research 14: 1079–1084.PubMedCrossRefGoogle Scholar
  27. Maulding, H.V., T.R. Tice, D.R. Cowsar, J.W. Fong, J.E. Pearson, and J.P. Nazareno. 1986. Biodegradable microcapsules: Acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament. Journal of Controlled Release 3: 103–117.CrossRefGoogle Scholar
  28. Naber, D. 2011. Olanzapine pamoate for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy 12: 627–633.PubMedCrossRefGoogle Scholar
  29. Naheed, M., and B. Green. 2001. Focus on clozapine. Current Medical Research and Opinion 17: 223–229.PubMedGoogle Scholar
  30. Park, E.J., T.H. Tak, D.H. Na, and K.C. Lee. 2010. Effect of PEGylation on stability of peptide in poly(lactide-co-glycolide) microspheres. Archives of Pharmacal Research 33: 1111–1116.PubMedCrossRefGoogle Scholar
  31. Rawat, A., E. Stippler, V.P. Shah, and D.J. Burgess. 2011. Validation of USP apparatus 4 method for microsphere in vitro release testing using Risperdal Consta. International Journal of Pharmaceutics 420: 198–205.PubMedCrossRefGoogle Scholar
  32. Rawat, A., U. Bhardwaj, and D.J. Burgess. 2012. Comparison of in vitro–in vivo release of Risperdal Consta microspheres. International Journal of Pharmaceutics 434: 115–121.PubMedCrossRefGoogle Scholar
  33. Risbood, V., J.R. Lee, J. Roche-Desilets, and M.A. Fuller. 2012. Lurasidone: An atypical antipsychotic for schizophrenia. Annals of Pharmacotherapy 46: 1033–1046.PubMedCrossRefGoogle Scholar
  34. Rössler, W., H.J. Salize, J. van Os, and A. Riecher-Rössler. 2005. Size of burden of schizophrenia and psychotic disorders. European Neuropsychopharmacology 15: 399–409.PubMedCrossRefGoogle Scholar
  35. Rubio, M.D., J.B. Drummond, and J.H. Meador-Woodruff. 2012. Glutamate receptor abnormalities in schizophrenia: Implications for innovative treatments. Biomolecules & Therapeutics 20: 1–18.CrossRefGoogle Scholar
  36. Samtani, M.N., A. Vermeulen, and K. Stuyckens. 2009. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: A novel once-monthly, long-acting formulation of an atypical antipsychotic. Clinical Pharmacokinetics 48: 585–600.PubMedCrossRefGoogle Scholar
  37. Sedky, K., R. Nazir, J.P. Lindenmayer, and S. Lippman. 2010. Paliperidone palmitate: Once monthly treatment option for schizophrenia. Current Psychiatry Online 9: 48–50.Google Scholar
  38. Selmin, F., P. Blasi, and P. P. Deluca. 2012. Accelerated polymer biodegradation of risperidone poly(d,l-lactide-co-glycolide) microspheres. AAPS Pharm Sci Tech 13: 1465–1472.Google Scholar
  39. Serajuddin, A.T. 2007. Salt formation to improve drug solubility. Advanced Drug Delivery Reviews 59: 603–616.PubMedCrossRefGoogle Scholar
  40. Shen, W.W. 1999. A history of antipsychotic drug development. Comprehensive Psychiatry 40: 407–414.PubMedCrossRefGoogle Scholar
  41. Shive, M.S., and J.M. Anderson. 1997. Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced Drug Delivery Reviews 28: 5–24.PubMedCrossRefGoogle Scholar
  42. Su, Z., F. Sun, Y. Shi, C. Jiang, Q. Meng, L. Teng, and Y. Li. 2009. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly(d,l-lactide-co-glycolide) microsphere. Chemical & Pharmaceutical Bulletin 57: 1251–1256.CrossRefGoogle Scholar
  43. Su, Z.X., Y.N. Shi, L.S. Teng, X. Li, L.X. Wang, Q.F. Meng, L.R. Teng, and Y.X. Li. 2011. Biodegradable poly(d,l-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation. Pharmaceutical Development and Technology 16: 377–384.PubMedCrossRefGoogle Scholar
  44. Tandon, R., and M.D. Jibson. 2002. Extrapyramidal side effects of antipsychotic treatment: Scope of problem and impact on outcome. Annals of Clinical Psychiatry 14: 123–129.PubMedCrossRefGoogle Scholar
  45. Taylor, D. 2009. Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review. British Journal of Psychiatry 52: S13–S19.CrossRefGoogle Scholar
  46. Valenstein, M., L.A. Copeland, R. Owen, F.C. Blow, and S. Visnic. 2001. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. Journal of Clinical Psychiatry 62: 545–551.PubMedCrossRefGoogle Scholar
  47. Wischke, C., and S.P. Schwendeman. 2008. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. International Journal of Pharmaceutics 364: 298–327.PubMedCrossRefGoogle Scholar
  48. Zuardi, A.W., A.C. Giampietro, and E.R. Grassi. 1983. Double-blind comparison between two forms of haloperidol: An oral preparation and a new depot decanoate in the maintenance of schizophrenic inpatients. Current Therapeutic Research 34: 253–261.Google Scholar

Copyright information

© The Pharmaceutical Society of Korea 2013

Authors and Affiliations

  • Eun Ji Park
    • 1
  • Sarmila Amatya
    • 2
  • Myung Sun Kim
    • 1
  • Jong Hoon Park
    • 3
  • Eunyoung Seol
    • 3
  • Heeyong Lee
    • 3
  • Young-Hee Shin
    • 2
  • Dong Hee Na
    • 1
  1. 1.College of Pharmacy and Research Institute of Pharmaceutical SciencesKyungpook National UniversityDaeguSouth Korea
  2. 2.College of Pharmacy, Kyungsung UniversityBusanSouth Korea
  3. 3.Peptron, Inc.DaejeonSouth Korea

Personalised recommendations